{"name":"Jack Khouri, MD","slug":"jack-khouri-md","ticker":"","exchange":"","domain":"","description":"Jack Khouri, MD is a specialty pharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. The company's primary focus is on oncology, particularly in the development of novel therapies for cancer. Despite having one drug in its pipeline, Teclistamab (FDA-approved), the company has discontinued further development of this product.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTUxZNTBtaThERFNFQUwzYThGY0FobHhibnZtVnVuZTJhUlNHOWFCeF9DV1JVdVJxX1hxclJMUjBZSzVUbGdUR1VaNEpSMnBwUHRZR29NR1ByTFZ3eWJBZ181ZnZZZDd4X0FfNzlLSHFLUjJtREpNNlRlLS1ZRHRjY0s3YTYzV3RZRHBDdjJ4UDVINHdtQkpqMV9fZC0tTEE0andranNhbXQ?oc=5","date":"2025-12-09","type":"trial","source":"Fierce Biotech","summary":"ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma - Fierce Biotech","headline":"ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNUUc3RFhtTW02M2std0VBN25hVXE1czVwdnJ0a1hHOWhBdVlyd3hwcDR1S3Jhd1RBbkxyYzU3V3cwV00xa1dXMjd6YTg3MVFhSlhRbFROeXpvQWZHbTJodktveHNSWjVBbzFfRDVaVm9IQWkyN1lveVpRbFhzVzRabWN3d19mZk11VzZJUlpYc1ZvSnpnNXhSRUlwQQ?oc=5","date":"2025-10-16","type":"pipeline","source":"The ASCO Post","summary":"Lisaftoclax Regimens Effective in Plasma Cell Disorders - The ASCO Post","headline":"Lisaftoclax Regimens Effective in Plasma Cell Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOaWI3UjBQVksza2tjekNTY2JuaWtWRU5NaTNVaktsQ0ZlT1Q0VHZMMDVfR2ZKcVB3R0M4MUpTNENKcFNac0RNOURHazJjYVIxeGgyVkRqRjE0OU9fcHFMSExxdUU4d09JN0drREpWZjBtZFFTeUg2NF80QWFFMHhzR0V3eUx4MmFUT2lPS0w5ZUVNQnFVdF9VQ3ExbG16THY5NkYzeFFsOTJ1YTJIcE96bEJIYWxZZmRvOGxPcnp3?oc=5","date":"2022-06-17","type":"pipeline","source":"Healio","summary":"Teclistamab confers durable benefit in advanced multiple myeloma - Healio","headline":"Teclistamab confers durable benefit in advanced multiple myeloma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}